PURPOSE: Generate content for a patient-reported outcome (PRO) measure for use in future clinical trials for inherited retinal degenerations. METHODS: Patients at the University of Michigan Kellogg Eye Center with a clinical diagnosis of inherited retinal degeneration with varying phenotypes were recruited for interviews. First, in-depth interviews were performed to solicit a wide range of patient experiences pertaining to visual function. Coders qualitatively analyzed the transcripts from these interviews using Atlas.ti software (Version 8.1.3 (522)) to draft questionnaire items. Next, the questionnaire was tested and refined based on participant feedback in cognitive interviews and administrator feedback in the pilot survey administration (pilot interviews). RESULTS: A total of 55 participants with a clinical diagnosis of inherited retinal degeneration were interviewed throughout the three study phases: in-depth interviews (n = 26), cognitive interviews (n = 16), and pilot interviews (n = 13). Coded items were analyzed for frequency of occurrence and related themes, then organized into common domains. Within each domain, PRO items were drafted to address the functional limitations or adaptations experienced by patients. CONCLUSIONS: Items for a PRO measure have been drafted and evaluated for interpretability in the target inherited retinal degeneration patient population. Content validity for the items was established through a process of in-depth interviews, cognitive interviews, and pilot interviews.
PURPOSE: Generate content for a patient-reported outcome (PRO) measure for use in future clinical trials for inherited retinal degenerations. METHODS:Patients at the University of Michigan Kellogg Eye Center with a clinical diagnosis of inherited retinal degeneration with varying phenotypes were recruited for interviews. First, in-depth interviews were performed to solicit a wide range of patient experiences pertaining to visual function. Coders qualitatively analyzed the transcripts from these interviews using Atlas.ti software (Version 8.1.3 (522)) to draft questionnaire items. Next, the questionnaire was tested and refined based on participant feedback in cognitive interviews and administrator feedback in the pilot survey administration (pilot interviews). RESULTS: A total of 55 participants with a clinical diagnosis of inherited retinal degeneration were interviewed throughout the three study phases: in-depth interviews (n = 26), cognitive interviews (n = 16), and pilot interviews (n = 13). Coded items were analyzed for frequency of occurrence and related themes, then organized into common domains. Within each domain, PRO items were drafted to address the functional limitations or adaptations experienced by patients. CONCLUSIONS: Items for a PRO measure have been drafted and evaluated for interpretability in the target inherited retinal degenerationpatient population. Content validity for the items was established through a process of in-depth interviews, cognitive interviews, and pilot interviews.
Authors: Mallika Prem Senthil; Jyoti Khadka; John De Roach; Tina Lamey; Terri McLaren; Isabella Campbell; Eva K Fenwick; Ecosse L Lamoureux; Konrad Pesudovs Journal: Optom Vis Sci Date: 2019-01 Impact factor: 1.973
Authors: Lidwine B Mokkink; Caroline B Terwee; Donald L Patrick; Jordi Alonso; Paul W Stratford; Dirk L Knol; Lex M Bouter; Henrica C W de Vet Journal: Qual Life Res Date: 2010-02-19 Impact factor: 4.147
Authors: Ava Katherine Bittner; Jennifer A Haythornthwaite; Marie Diener-West; Gislin Dagnelie Journal: Br J Ophthalmol Date: 2012-12-04 Impact factor: 4.638
Authors: Debra A Thompson; Robin R Ali; Eyal Banin; Kari E Branham; John G Flannery; David M Gamm; William W Hauswirth; John R Heckenlively; Alessandro Iannaccone; K Thiran Jayasundera; Naheed W Khan; Robert S Molday; Mark E Pennesi; Thomas A Reh; Richard G Weleber; David N Zacks Journal: Invest Ophthalmol Vis Sci Date: 2015-02-09 Impact factor: 4.799
Authors: Erin Zampaglione; Benyam Kinde; Emily M Place; Daniel Navarro-Gomez; Matthew Maher; Farzad Jamshidi; Sherwin Nassiri; J Alex Mazzone; Caitlin Finn; Dana Schlegel; Jason Comander; Eric A Pierce; Kinga M Bujakowska Journal: Genet Med Date: 2020-02-10 Impact factor: 8.822
Authors: Robert E MacLaren; Markus Groppe; Alun R Barnard; Charles L Cottriall; Tanya Tolmachova; Len Seymour; K Reed Clark; Matthew J During; Frans P M Cremers; Graeme C M Black; Andrew J Lotery; Susan M Downes; Andrew R Webster; Miguel C Seabra Journal: Lancet Date: 2014-01-16 Impact factor: 79.321
Authors: Gabrielle D Lacy; Maria Fernanda Abalem; Chris A Andrews; Rebhi Abuzaitoun; Lilia T Popova; Erin P Santos; Gina Yu; Hanan Y Rakine; Natasha Baig; Joshua R Ehrlich; Abigail T Fahim; Kari H Branham; Bonnielin K Swenor; Paul R Lichter; Gislin Dagnelie; Joan A Stelmack; David C Musch; K Thiran Jayasundera Journal: Am J Ophthalmol Date: 2020-12-09 Impact factor: 5.258
Authors: Gabrielle D Lacy; Maria Fernanda Abalem; Chris A Andrews; Lilia T Popova; Erin P Santos; Gina Yu; Hanan Y Rakine; Natasha Baig; Joshua R Ehrlich; Abigail T Fahim; Kari H Branham; Joan A Stelmack; Bonnielin K Swenor; Gislin Dagnelie; David C Musch; K Thiran Jayasundera Journal: Am J Ophthalmol Date: 2020-08-26 Impact factor: 5.258